Nicast News
2 articles
growth-positive
Vascular access graft maker Nicast gets CE Mark, raises funds
Medical device company Nicast Ltd. has obtained EU CE Mark certification for its AVflo vascular access graft for hemodialysis treatment. The company has raised $2.5 million from its current investors, Azrieli Group, Israel Infinity Venture Capital, and a group of private investors. Nicast plans to raise an additional $10 million in 2009. The company was founded in 1995 and has since focused on a range of medical products. Nicasts AVflo device is more flexible than current vascular graft products and its unique electrospun nanofabric spontaneously seals the punctures in the blood vessel.
Investment
growth-positive
Nicast Raises $1 Million BioSpace
Nicast, a provider of artificial replacement for human tissues, offers artificial blood vessels for bypass surgery and peripheral use. The companys vascular products are created using a unique manufacturing technology. The article does not mention any specific impact on the company, investors, or partners. The key theme of the article is the companys medical technology products. The article does not mention any customers, acquisition or investment amounts, layoffs, or a specific date of the event. The confidence level of the answer is 8.
CustomersPartners
